0.3600SEK0.00%Mkt Cap: 105.09M SEKP/E: —Last update: 2026-06-01
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of Am…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap105.09M SEK
Enterprise Value21.70M SEK
Revenue (TTM)10.93M SEK
Gross Profit8.09M SEK
Net Income (TTM)-87.62M SEK
Revenue/Share0.0590 SEK
Last Price0.3600 SEK
Fiscal Year EndApr 2025
MR QuarterJan 2026
Employees24
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.35
PEG—
EV/EBITDA-0.30
EV/Revenue1.99
P/S9.62
P/B0.99
EPS (TTM)-0.44
EPS (Forward)-1.04
52W Range
0.270014% of range0.8980
52W High0.8980 SEK
52W Low0.2700 SEK
Profitability
Gross Margin93.79%
Oper. Margin-543.14%
EBITDA Margin0.00%
Profit Margin-1016.52%
ROE-202.81%
ROA-134.91%
Growth
Revenue Growth45.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-85.37M SEK
CapEx (TTM)287.00K SEK
FCF Margin-359.77%
FCF Yield-37.40%
Net Debt-83.39M SEK
Net Debt/EBITDA1.14
Balance Sheet
Debt/Equity0.11
Current Ratio5.42
Quick Ratio5.30
Book Value/Sh0.3630 SEK
Cash/Share0.3020 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)0.7000 SEK
Target Range0.7000 SEK – 0.7000 SEK
# Analysts1
Ownership
Shares Out.277.49M
Float252.32M
Insiders0.00%
Institutions0.01%
Technical
SMA 500.3455 (+4.2%)
SMA 2000.4590 (-21.6%)
Beta1.09
S&P 52W Chg27.70%
Avg Vol (30d)438.41K
Avg Vol (10d)532.87K
Technical Indicators
RSI (14)55.5
MACD0.0000
MACD Signal-0.0027
MACD Hist.+0.0027
BB Upper0.3662 SEK
BB Middle0.3383 SEK
BB Lower0.3104 SEK
BB Width16.50%
ATR (14)0.0295 SEK
Vol Ratio (20d)1.16x